scholarly journals Requirement of c-kit for development of intestinal pacemaker system

Development ◽  
1992 ◽  
Vol 116 (2) ◽  
pp. 369-375 ◽  
Author(s):  
H. Maeda ◽  
A. Yamagata ◽  
S. Nishikawa ◽  
K. Yoshinaga ◽  
S. Kobayashi ◽  
...  

A discovery that the protooncogene encoding the receptor tyrosine kinase, c-kit, is allelic with the Dominant white spotting (W) locus establishes that c-kit plays a functional role in the development of three cell lineages, melanocyte, germ cell, and hematopoietic cell which are defective in W mutant mice. Recent analyses of c-kit expression in various tissues of mouse, however, have demonstrated that c-kit is expressed in more diverse tissues which are phenotypically normal in W mutant mice. Thus, whether or not c-kit expressed outside the three known cell lineages plays a functional role is one of the important questions needing answering in order to fully elucidate the role of c-kit in the development of the mouse. Here, we report that some of the cells in smooth muscle layers of developing intestine express c-kit. Blockade of its function for a few days postnatally by an antagonistic anti-c-kit monoclonal antibody (mAb) results in a severe anomaly of gut movement, which in BALB/c mice produces a lethal paralytic ileus. Physiological analysis indicates that the mechanisms required for the autonomic pacing of contraction in an isolated gut segment are defective in the anti-c-kit mAb-treated mice, W/Wv mice and even W/+ mice. These findings suggest that c-kit plays a crucial role in the development of a component of the pacemaker system that is required for the generation of autonomic gut motility.

2016 ◽  
Vol 244 ◽  
pp. e3-e4 ◽  
Author(s):  
F. Yang ◽  
Q. Chen ◽  
G. Wen ◽  
C. Zhang ◽  
L.A. Luong ◽  
...  

1997 ◽  
Vol 47 (2) ◽  
pp. 149-158 ◽  
Author(s):  
T. Sakaguchi ◽  
Y. Takamiya ◽  
Michael Edidin ◽  
Kiyoshi Nokihara ◽  
Kiyoshi Miwa ◽  
...  

2003 ◽  
Vol 138 (5) ◽  
pp. 757-766 ◽  
Author(s):  
Alexandra Wibberley ◽  
Zunxuan Chen ◽  
Erding Hu ◽  
J Paul Hieble ◽  
Timothy D Westfall

2012 ◽  
Vol 30 ◽  
pp. e33
Author(s):  
Vibeke Secher Dam ◽  
Torbjarn Bragger ◽  
Donna Badtkjer ◽  
Christian Aalkjalr ◽  
Vladimir Matchkov

2010 ◽  
Vol 5 (2) ◽  
pp. 95 ◽  
Author(s):  
Olivier Benveniste ◽  
David Hilton-Jones ◽  
◽  

Rituximab, a chimaeric monoclonal antibody against CD20, depletes B cells. It was initially approved for the treatment of B-cell lymphomas, but more recently has been approved for use in rheumatoid arthritis. It has been used extensively ‘off-label’ for the treatment of other autoimmune diseases with some evidence of efficacy, but there remain some as yet unanswered concerns about safety. Myasthenia gravis is the paradigm of an antibody-mediated disorder, and B cells are believed to play a crucial role. This article reviews experience of the efficacy and safety of rituximab in myasthenia gravis and considers predictive factors for the success and failure of rituximab in this disease.


Sign in / Sign up

Export Citation Format

Share Document